The Biden Administration's Push for Transparency in AI Technology
Successor Government Contractor Hiring Obligations Change: DOL’s Long Awaited Nondisplacement Rule
Protecting Our Nation’s Data: Cybersecurity Compliance for Government Contractors
AI Around the Globe: What to Know in 2024
DE Under 3: President Biden Issued "Modernizing Regulatory Review" Executive Order
Business Better Podcast Episode: An Update on Environmental Justice Under the Biden Administration
#WorkforceWednesday: FTC Proposes Ban on Non-Competes - Employment Law This Week® - Spilling Secrets Podcast
Constangy Webinar - DEI Audits: Tools to Enhance Your DEI Practices
Navigating the FTC’s Proposed Rule Banning Non-Competes
Exploring the FTC’s Proposed Ban on Noncompetes (Fairly Competing, Episode 20)
Law Brief®: Rich Schoenstein and David Kleinmann Discuss FTC's Proposed Noncompete Ban
[Podcast] Keith Matthews and Chris Wozniak: Talking Ag Biotech Episode 2
Bringing order to the regulatory chaos for crypto?
DE Under 3: New Data Collection Burdens, NLRB’s Ruling Regarding Union Election Dismissals, and OMB’s Tech Modernization Fund
The Labor Law Insider: Project Labor Agreements Part II
JONES DAY PRESENTS®: Crypto Markets Expand as Biden Calls for All-of-Government Approach to Regs
DE Under 3: EEO-1 Survey Closure Date, Non-Binary Reporting Updates, and Government Agency Equity Plans
#WorkforceWednesday: Non-Compete Compliance, New Requirements for Plan Sponsors, Get Ahead on Anti-Harassment Training - Employment Law This Week®
Congressional and Federal Agency Action Following Executive Order on Digital Assets Policy
DE Under 3: OFCCP AAP Verification Portal 'Rules of Behavior', Vaccination Injunction Updates, & Recent Job Scam Alerts
As 2022 comes to a close, we review Big Molecule Watch’s top five biosimilar regulatory developments of the year...more
On July 6, 2022, Katherine Vidal, the Undersecretary of Commerce for Intellectual Property and Director of the USPTO, published her response to the letter sent by Janet Woodcock (former acting FDA Commissioner) to the former...more
2021 saw several important milestones in the biosimilars space, including the much anticipated first interchangeable designations by FDA and the approval of the first ophthalmology biosimilar. The biosimilar market also...more
USPTO News - On September 9, 2021, Senators Patrick Leahy and Thom Tillis wrote a letter to Acting Director Andrew Hirshfeld requesting that the USPTO “take steps to reduce patent applicants’ making inappropriate...more